Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis

Laura Ambra Nicolini; Paola Canepa; Patrizia Caligiuri; Malgorzata Mikulska; Giovanni Novi; Claudio Viscoli; Antonio Uccelli

doi:10.1001/jamaneurol.2019.0522

Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis

JAMA Neurol. 2019 Jul 1;76(7):866-867. doi: 10.1001/jamaneurol.2019.0522.

Authors

Laura Ambra Nicolini^{1

2}, Paola Canepa¹, Patrizia Caligiuri¹, Malgorzata Mikulska^{1

2}, Giovanni Novi³, Claudio Viscoli^{1

2}, Antonio Uccelli^{3

4}

Affiliations

¹ Department of Health Sciences, University of Genoa, Genoa, Italy.
² Infectious Diseases Unit, Ospedale Policlinico San Martino-Istituto Di Ricovero e Cura a Carattere Scientifico, Genoa, Italy.
³ Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health and Center of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
⁴ Ospedale Policlinico San Martino-Istituto Di Ricovero e Cura a Carattere Scientifico, Genoa, Italy.

Abstract

This case study describes a patient in whom administration of an anti-CD20 antibody to treat multiple sclerosis appears to have precipitated liver failure.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects*
Basiliximab / therapeutic use
Echovirus Infections / immunology
Echovirus Infections / virology*
Female
Graft Rejection / prevention & control
Humans
Immunocompromised Host*
Immunologic Factors / adverse effects*
Immunosuppressive Agents / therapeutic use
Liver Transplantation
Massive Hepatic Necrosis / immunology
Massive Hepatic Necrosis / surgery
Massive Hepatic Necrosis / virology*
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Tacrolimus / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
Immunosuppressive Agents
Basiliximab
ocrelizumab
Tacrolimus